Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Project Orbis 2023: FDA Approves Six New Cancer Drugs, But Partner Nations Lag Behind

Dec 05 2023

• By Eliza Slawther

Globe With Medicines — • Source: Shutterstock

Related Content

Australian Regulator On The Highs & Lows Of Project Orbis

May 04 2022

Pink Sheet Podcast: US FDA Launches Project Orbis And The Rare Disease Cures Accelerator, Looks For Abuse-Deterrent CNS Drugs

Sep 20 2019

International Regulators Say Collaboration Is Key To Tackling Pharma Globalization Challenges

Oct 25 2023

Swissmedic On Project Orbis: Faster Access To Drugs, Valuable Scientific Discussions

Oct 05 2023

EMA Backs Approval Of Santhera’s Agamree, Pfizer’s Elrexfio & Several Other New Drugs

Oct 13 2023

How Does The ACCESS Consortium Compare To Project Orbis?

Oct 31 2023

Keeping Track: Pfizer And J&J’s Dueling Myeloma Bispecifics; Regeneron And Ipsen Nab Priority Vouchers

Aug 21 2023

English Funding Nod For Lilly’s Diabetes GLP-1 Mounjaro, Roche’s Cancer MAb Columvi

Sep 08 2023

Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs

Mar 13 2023

A Month After Lung Cancer Withdrawal, Takeda Gets Approval For New Colorectal Cancer Drug

Nov 09 2023

Related Companies

Pfizer Inc.

Roche Holding AG

Genentech, Inc.

Janssen Pharmaceuticals Inc.

Coherus Oncology, Inc.

Takeda Pharmaceutical Co. Ltd.

AstraZeneca LP

MSD

GSK plc

Novartis AG

Gilead Sciences, Inc.

Seagen Inc.

Astellas Pharma, Inc.

Amgen, Inc.

Additional Topics

Europe US States International Australia Asia Pacific Singapore Switzerland United Kingdom Canada Brazil South America Market Access Regulation Review Pathway Regional Comparisons Innovation ImmunoOncology Drug Review Approvals BioPharmaceutical Cancer

More from Market Access

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window